刘宏民
郑州大学药学院教授，硕士生导师/博士生导师，药物关键制备技术教育部重点实验室主任
邮箱：liuhm@zzu.edu.cn
个人简介
刘宏民，博士生导师，教育部重点实验室主任，省部共建国家重点实验室副主任，中国药学会药物化专委会委员，河南省生物医药产业技术创新战略联盟理事长，中国民主促进会中央委员，河南省政协委员等职务。先后获国家有突出贡献中青年专家，政府特殊津贴专家，全国优秀教师，宝钢优秀教师奖等荣誉称号，2016年入选中原学者。先后主持国家重大新药创制专项，国家新技术产业化项目，国家重点研发计划，国家科技支撑计划项目，国家自然科学基重点项目等多项国家级重大或重点项目。开发了倍他洛尔等国家新药，克林霉素磷酸酯等多项药物与药物中间体合成新工艺被企业采用。获省科技进步一等奖1项、二等奖3项。发表SCI论文400多篇，授权国家发明专利60余项，培养愽士生，硕士生和博士后研究人员150余人。
科研项目
1）国家自然科学基金委员会，联合基金项目，U21A20416，HDAC6及SHP2对食管癌免疫逃逸的表观遗传调控及其靶向小分子抑制剂干预研究，2021-01至2025-12，260万元，在研，主持。
2）国家自然科学基金委员会，国际(地区)合作与交流项目，82020108030，USP7对胃癌细胞转移、增殖和免疫逃逸的调节机制及小分子化合物干预研究，2021-01至2025-12，248万元，在研，主持。
3）科技部政府间国际科技创新合作重点专项，2018YFE0195100，LSD1类泛素化修饰对胃癌转移的调控作用及小分子干预研究，201901-202212，276万元，已结题，主持。
4）国家自然科学基金委员会，面上项目，81773562，UBC12-DCN1靶向小分子抑制剂的设计、合成及其在胃癌中对NEDDylation的调控机制研究，2018-01至2021-12，53万元，已结题，主持。
5）国家自然科学基金委员会，重点项目，81430085，胃癌细胞LSD1与EMT通路相关蛋白相互作用的机制及小分子抑制剂干预研究，2015-01至2019-12，320万元，已结题，主持
6）国家自然科学基金委员会，面上项目，21372206，基于甾体的螺羟基吲哚衍生物小分子库的构建及其抗肿瘤活性评价，2014-01至2017-12，85万元，已结题，主持。
7）横向项目，20200178A，那格列奈等药物绿色生产工艺的研究与开发，202001-202212，300万，已结题，主持。
8）横向项目，20220332A，盐酸氮芥酊制备工艺的研究与开发，202201-202412，150万，已结题，主持。
研究与成果
(1) Liang Shen#, Bo Wang#, Shao-Peng Wang, Shi-Kun Ji, Meng-Jie Fu, Shu-Wu Wang,Wen-Qing Hou, Xing-Jie Dai*, Hong-Min Liu*. Combination therapy and dual-target inhibitors based on LSD1: New emerging tools in cancer therapy. Journal of Medicinal Chemistry, 2024, 67(2): 922-951.
(2) Xing-Jie Dai#, Li-Juan Zhao#, Long-Hua Yang#, Ting Guo, Lei-Peng Xue, Hong-Mei Ren, Zhi-Li Yin, Xiao-Peng Xiong, Ying Zhou, Shi-Kun Ji, Hui-Min Liu, Hong-Min Liu*, Ying Liu*, Yi-Chao Zheng*. Phenothiazine-based LSD1 inhibitor promotes T-cell killing response of gastric cancer cells. Journal of Medicinal Chemistry, 2023, 66(6):3896–3916.
(3) Dan-Dan Shen, Jing-Ru Pang, Ya-Ping Bi, Long-Fei Zhao, Yin-Rui Li, Li-Juan Zhao, Ya Gao, Bo Wang, Ning Wang, Liuya Wei, Huiqin Guo, Hong-Min Liu* and Yi-Chao Zheng*. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Molecular Cancer, 2022, 21: 75.
(4) Li-Juan Zhao, Ying-Ying Li, Yu-Tong Zhang, Qi-Qi Fan, Hong-Mei Ren, Cheng
Zhang, Adil Mardinoglu, Wen-Chao Chen, Jing-Ru Pang, Dan-Dan Shen, Jun-Wei Wang, Long- Fei Zhao, Jian-Ying Zhang, Zhen-Ya Wang, Yi-Chao Zheng* and Hong-Min Liu*. Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. Embo Reports, 2021, e50922.
(5) Liying Ma, Haojie Wang, Yinghua You, Chaoya Ma, Yuejiao Liu, Feifei Yang, Yichao Zheng*, Hongmin Liu*. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors. Acta Pharmaceutica Sinica B, 2020, 10(6): 1658-1668.
(6) Xing-Jie Dai, Ying Liu, Lei-Peng Xue, Xiao-Peng Xiong, Ying Zhou, Yi-Chao Zheng*, Hong-Min Liu*. Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1. Journal of Medicinal Chemistry, 2021, 64(5): 2466-2488.
(7) Zhonghua Li#, Lina Ding#, Zhongrui Li#, Zhizheng Wang, Fengzhi Suo, Dandan Shen, Taoqian Zhao, Xudong Sun, Junwei Wang, Ying Liu, Liying Ma, Bing Zhao, Pengfei Geng, Bin Yu*, Yichao Zheng*, Hongmin Liu*, Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Acta Pharmaceutica Sinica B. 2019, 9(4): 794-808.
(8) Pengxing He#, ShenghuiNiu#, Shuai Wang#, Xiaojing Shi, SiqiFeng, Linna Du, Xuyang Zhang, Zhilu Ma, Bin Yu*, Hongmin Liu*, Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta Pharmaceutica Sinica B, 2019, 6: 1193-1203.
(9) Shuai Wang#, Lijie Zhao#, Xiao-Jing Shi#, Lina Ding#, Linlin Yang, Zhi-Zheng Wang, Dandan Shen, Kai Tang, Xiao-Jing Li, MAA Mamun, Huiju Li, Bin Yu*, Yi-Chao Zheng*, Shaomeng Wang*, Hong-Min Liu*, Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 5: 2772-2797.
(10) Wenjuan Zhou#, Liying Ma#, Lina Ding, QianGuo, Zhangxu He, Jing Yang, Hui Qiao, Lingyu Li, Jie Yang, Shimin Yu, Lili Zhao, Shaomeng Wang, Hongmin Liu*, ZhenheSuo*, Wen Zhao*. Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1–UBE2M Interaction. Journal of Medicinal Chemistry, 2019, 62, 11: 5382-5403.
(11) Xing-Jie Dai, Ying Liu, Xiao-Peng Xiong, Lei-Peng Xue, Yi-Chao Zheng*, Hong-Min Liu*. Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective. Journal of Medicinal Chemistry, 2020, 63(23): 14197-14215.
(12) Li-Ying Ma#, Yi-Chao Zheng#, Sai-Qi Wang#, Bo Wang, Zhi-Ru Wang, Lu-Ping Pang, Miao-Zhang, Jun-Wei Wang, Li-Na Ding, Juan Li, Cong Wang, Biao Hu, Ying Liu, Xiao-Dan Zhang, Jia-Jia Wang, Zhi-Jian Wang, Wen Zhao*, Hong-Ming Liu*, Design, synthesis and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea-hybrids as potent, orally active antitumor agents. Journal of Medicinal Chemistry, 2015, 58: 1705-1716.
(13) Yi-Chao Zheng#, Ying-Chao Duan#, Jin-Lian Ma, Rui-Min Xu, Xiaolin Zi, Wen-Lei Lv, Meng-Meng Wang, Xian-Wei Ye, Shun Zhu, David Mobley, Yan-Yan Zhu, Jun-Wei Wang, Jin-Feng Li, Zhi-Ru Wang, Wen Zhao, Hong-Min Liu. Triazole-dithiocarbamate based, selective LSD1 inactivators inhibit gastric cancer cell growth, invasion and migration. Journal of Medicinal Chemistry, 2013, 56, 8543-8560.
